Three-month romosozumab followed by denosumab is noninferior to a 12-month course for total hip BMD gains in postmenopausal osteoporosis.
Please provide your email address to receive an email when new articles are posted on . Researchers determined baseline BMD T-score cutoffs for achieving a T-score of higher than –2.5 with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results